Literature DB >> 18496262

Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic.

Allan Gibofsky1, Robert L Barkin.   

Abstract

Chronic/persistent pain due to osteoarthritis is one of the most common pain conditions affecting Americans today. Inadequate pain relief or dissatisfaction with current treatments is a source of frustration and suffering for patients with chronic/persistent pain. The requirement of multiple doses of commonly used analgesics to maintain adequate pain relief is inconvenient for many patients with osteoarthritis-related chronic pain. The several extended-release opioid analgesics that have been developed may provide an opportunity for improved patient convenience; however, clinicians must consider adverse event profiles, pharmacokinetics, abuse potential, and controlled substance-scheduling status of extended-release opioid analgesics. The purpose of this review is to highlight the efficacy and safety of extended-release opioid analgesics utilized in the management plan of chronic pain due to osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18496262     DOI: 10.1097/MJT.0b013e3181727f68

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  6 in total

1.  Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.

Authors:  Marc Afilalo; Mila S Etropolski; Brigitte Kuperwasser; Kathy Kelly; Akiko Okamoto; Ilse Van Hove; Achim Steup; Bernd Lange; Christine Rauschkolb; Juergen Haeussler
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Kappa and delta opioid receptor signaling is augmented in the failing heart.

Authors:  Craig Bolte; Gilbert Newman; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2009-06-30       Impact factor: 5.000

3.  Update on prescription extended-release opioids and appropriate patient selection.

Authors:  Michael J Brennan
Journal:  J Multidiscip Healthc       Date:  2013-07-23

4.  Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model.

Authors:  Giovanna Desando; Carola Cavallo; Federica Sartoni; Lucia Martini; Annapaola Parrilli; Francesca Veronesi; Milena Fini; Roberto Giardino; Andrea Facchini; Brunella Grigolo
Journal:  Arthritis Res Ther       Date:  2013-01-29       Impact factor: 5.156

5.  Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature.

Authors:  Robert Taylor; Robert B Raffa; Joseph V Pergolizzi
Journal:  J Pain Res       Date:  2012-04-23       Impact factor: 3.133

Review 6.  Tramadol Extended-Release for the Management of Pain due to Osteoarthritis.

Authors:  Chiara Angeletti; Cristiana Guetti; Antonella Paladini; Giustino Varrassi
Journal:  ISRN Pain       Date:  2013-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.